A New Calcium(II)-Based Substitute for Enrofloxacin with Improved Medicinal Potential.

Enrofloxacin (EFX) reacting with Ca(II) afforded a new complex, [Ca(EFX)(HO)] (EFX-Ca), which was structurally characterized both in solid and solution chemistry. and were tested to be the most sensitive strains for EFX-Ca. The LD value of EFX-Ca in mice was 7736 mg/kg, implying the coordination of EFX to Ca(II) effectively reduced its acute toxicity.

Structural characterization and pharmacological assessment / of a new copper(II)-based derivative of enrofloxacin.

Enrofloxacin (EFX) was selected as the medicinal ligand to afford a new copper(ii)-based complex, EFX-Cu, which was structurally characterized by spectroscopic analyses including X-ray single crystal diffraction. It was also stable and could retain the coordination state in aqueous solution. The in vitro antibacterial activity of EFX-Cu against a panel of pathogenic bacteria was about the same as that of EFX, except that it was twice as active against E.